Sequenom reiterated at Buy at Maxim

|By:, SA News Editor

Sequenom (SQNM -0.2%) gets a vote of confidence from Maxim's Bryan Brokmeier who reiterates the shares at Buy following the company's Q3 results.

"The reimbursement environment remains challenging [but] we're increasingly optimistic," Brokmeier notes, citing the percentage of diagnostic revenue from international, the Q/Q rise in covered lives, and the fact that "all major national payers are reimbursing the MaterniT21."

Price target is $6.